Articles

Single-Agent Nivolumab in Advanced NSCLC

ASCO 2014 – Immuno-Oncology

Nivolumab Combined with Platinum-Based Doublet Chemotherapy in Advanced NSCLC

ASCO 2014 – Immuno-Oncology

Gefitinib Plus Carboplatin/Pemetrexed as First-Line Therapy of EGFR+ NSCLC

ASCO 2014 – Lung Cancer

First-Line Nivolumab Monotherapy in Advanced NSCLC

ASCO 2014 – Lung Cancer

Results from the ARCHER 1009 Study: Dacomitinib Versus Erlotinib for Second-/Third-Line Therapy of Locally Advanced or Metastatic NSCLC

ASCO 2014 – Lung Cancer

Results from PROFILE 1014: First-Line Crizotinib Versus Pemetrexed-Platinum in ALK+ NSCLC

ASCO 2014 – Lung Cancer

Erlotinib Plus Bevacizumab as First-Line Treatment for EGFR+, Advanced NSCLC

ASCO 2014 – Lung Cancer

Phase 2 Trial of Nivolumab in Metastatic Renal Cell Carcinoma

ASCO 2014 – Immuno-Oncology

Ceritinib in Advanced ALK-Rearranged NSCLC: Results from the ASCEND-1 Trial

ASCO 2014 – Lung Cancer

Docetaxel and Cisplatin Plus Chemoradiation in Inoperable Stage III NSCLC

ASCO 2014 – Lung Cancer

Page 142 of 147